Processa Pharmaceuticals, Inc. (PCSA): auditor change — Processa Pharmaceuticals replaces auditor BD & Co. with Cherry Bekaert

Processa Pharmaceuticals, Inc.

BD & Co. resigned Oct 31, 2024 after merger into Citrin Cooperman; no disagreements or reportable events.
Audit Committee appointed Cherry Bekaert LLP for FY 2024 and subsequent interim periods.
No prior consultations with Cherry Bekaert regarding accounting principles or disagreements.
BD & Co.'s audit reports for 2023 and 2022 were unqualified and contained no adverse opinion.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

BD & Company., Inc. resigned as auditor of Processa Pharmaceuticals, Inc..

Action: resignation
Auditor: BD & Company., Inc.
Successor: Cherry Bekaert LLP

Exact text from the filing

On October 31, 2024, BD & Company., Inc. ("BD & Co") merged in Citrin Cooperman and resigned as the Company’s independent registered public accounting firm.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Processa Pharmaceuticals, Inc. engaged Cherry Bekaert LLP as its auditor.

Action: engagement
Auditor: Cherry Bekaert LLP

Exact text from the filing

On November 6, 2024, the Audit Committee approved the engagement of Cherry Bekaert LLP ("Cherry Bekaert") as its new independent registered public accounting firm.

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

Processa Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-043821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.